Diagnosis and management of intestinal Behçet's diseas

Tadakazu Hisamatsu, Makoto Naganuma, Katsuyoshi Matsuoka, Takanori Kanai

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)

Abstract

Behçets disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalClinical journal of gastroenterology
Volume7
Issue number3
DOIs
Publication statusPublished - 2014 Jun

Keywords

  • Adalimumab
  • Anti-TNFα mAb
  • Intestinal Behçets disease
  • Trisomy 8

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Diagnosis and management of intestinal Behçet's diseas'. Together they form a unique fingerprint.

Cite this